I5Q-MC-CGAT - ClinicalTrials.gov - NCT04616326
I5Q-MC-CGAT - ClinicalTrials.gov - NCT04616326
Key Requirements
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Patients must have a diagnosis of chronic migraine as defined by the IHS ICHD-3 guidelines (1.3 according to ICHD-3 [2018]), that is, a headache occurring on 15 or more days per month for at least the last 3 months, which has the features of migraine headache on at least 8 days per month
Participants must NOT
Participants must not be allergic to multiple drugs or certain types of drugs sometimes used for headaches
Participants must not have a history of persistent headaches every day or cluster headaches
Participants must not have a history of head or neck injury that was associated with the start of migraine headaches or a change in the nature of their headaches
Participants must not have a history of brain tumors or birth defects of the brain
Trial Summary
Conditions the trial is for
Pediatric Migraine, Migraine
What the trial is testing?
Galcanezumab
Could I receive a Placebo?
yes
Enrollment Goal
300
Trial Dates
November 2020 - March 2024
Trial Phase
3
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Patients must have a diagnosis of chronic migraine as defined by the IHS ICHD-3 guidelines (1.3 according to ICHD-3 [2018]), that is, a headache occurring on 15 or more days per month for at least the last 3 months, which has the features of migraine headache on at least 8 days per month
Participants must NOT
Participants must not be allergic to multiple drugs or certain types of drugs sometimes used for headaches
Participants must not have a history of persistent headaches every day or cluster headaches
Participants must not have a history of head or neck injury that was associated with the start of migraine headaches or a change in the nature of their headaches
Participants must not have a history of brain tumors or birth defects of the brain
Trial Summary
Conditions the trial is for
Pediatric Migraine, Migraine
What the trial is testing?
Galcanezumab
Could I receive a Placebo?
yes
Enrollment Goal
300
Trial Dates
November 2020 - March 2024
Trial Phase
3
Trial Locations
Hide locations not currently recruiting